GlassScriptPhysician profile
Daxa D Patel
NPI 1487730545
$2,332.39
in general payments reported to CMS, 2019-2025
23 companies · $647 in 2025
The $647 reported for 2025 was more than what 80% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $209 · 2021: $262 · 2022: $310 · 2023: $357 · 2024: $324 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.74 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $486.77 | 2021-2025 | |
| Hologic Sales and Service, LLC | $287.13 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Fluent Fluid Management System |
| Astellas Pharma US INC | $248.94 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $225.81 | 2019-2025 | |
| Abbvie INC. | $185.98 | 2019-2022 | |
| Millicent US INC | $147.19 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $116.41 | 2020-2025 | Slynd |
| Sumitomo Pharma America, INC. | $82.51 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $79.86 | 2019-2022 | |
| Myovant Sciences INC. | $68.57 | 2021-2022 | |
| Exact Sciences Corporation | $57.43 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Avion Pharmaceuticals | $51.01 | 2019-2023 | Balcoltra |
| Allergan, INC. | $47.68 | 2019 | |
| Coopersurgical, INC. | $45.94 | 2021-2024 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $39.84 | 2019-2023 | Gardasil 9 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.03 | 2022-2023 | |
| Agile Therapeutics, INC. | $26.28 | 2021 | |
| Minerva Surgical, INC | $20.23 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.90 | 2019 | |
| Organon LLC | $17.78 | 2025 | |
| Lupin INC. | $17.02 | 2020 | |
| Glaxosmithkline, LLC. | $16.12 | 2023 | Fluarix Quadrivalent |
| Channel Medsystems, INC. | $11.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daxa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.